Reilly Financial Advisors’s Galmed Pharmaceuticals GLMD Stock Holding History

Reilly Financial Advisors’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1	Closed	-$1K	–	1029
2021 Q1	$1K	Hold	1	–	–	﹤0.01%	987
2020 Q4	$1K	Hold	1	–	–	﹤0.01%	852
2020 Q3	$1K	Hold	1	–	–	﹤0.01%	796
2020 Q2	$1K	Hold	1	–	–	﹤0.01%	849
2020 Q1	$1K	Hold	1	–	–	﹤0.01%	835
2019 Q4	$1K	Hold	1	–	–	﹤0.01%	844
2019 Q3	$1K	Hold	1	–	–	﹤0.01%	855
2019 Q2	$2K	Hold	1	–	–	﹤0.01%	863
2019 Q1	$2K	Hold	1	–	–	﹤0.01%	881
2018 Q4	$2K	Hold	1	–	–	﹤0.01%	852
2018 Q3	$3K	Hold	1	–	–	﹤0.01%	897
2018 Q2	$3K	Hold	1	–	–	﹤0.01%	880
2018 Q1	$1K	Hold	1	–	–	﹤0.01%	922
2017 Q4	$2K	Hold	1	–	–	﹤0.01%	878
2017 Q3	$2K	Hold	1	–	–	﹤0.01%	889
2017 Q2	$2K	Hold	1	–	–	﹤0.01%	869
2017 Q1	$1K	Hold	1	–	–	﹤0.01%	877
2016 Q4	$1K	Hold	1	–	–	﹤0.01%	796
2016 Q3	$1K	Hold	1	–	–	﹤0.01%	793
2016 Q2	$1K	Hold	1	–	–	﹤0.01%	760
2016 Q1	$1K	Buy	+1	New	+$980	﹤0.01%	1122

Other funds holding GLMD

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Reilly Financial Advisors's GLMD Position: Q2 2021 in Review

Reilly Financial Advisors sold out of Galmed Pharmaceuticals (GLMD) in Q2 2021, closing a stake of 1 share — an estimated $1K sold.

Reilly Financial Advisors first reported a position in GLMD in Q1 2016 and held it in 21 quarters. The position peaked at $3K in Q3 2018. 25 funds tracked by Wall St. Rank hold GLMD as of Q2 2021.

Reilly Financial Advisors reported no remaining Galmed Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Reilly Financial Advisors sold 1 Galmed Pharmaceuticals share in Q2 2021, an estimated $1K.
Reilly Financial Advisors first reported a position in Galmed Pharmaceuticals in Q1 2016 and held it in 21 quarters.
Reilly Financial Advisors's Galmed Pharmaceuticals position peaked at $3K in Q3 2018.
25 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q2 2021.

Based on Reilly Financial Advisors's 13F filing for Q2 2021, filed 3 Aug 2021.